Stockscreener 앱 받기
54.53
3.14%
-1.77
시간 외 거래:
54.55
0.02
+0.04%
전일 마감가:
$56.30
열려 있는:
$56.24
하루 거래량:
1.54M
Relative Volume:
0.72
시가총액:
$10.49B
수익:
$3.24B
순이익/손실:
$348.90M
주가수익비율:
30.61
EPS:
1.7817
순현금흐름:
$717.02M
1주 성능:
-1.75%
1개월 성능:
-10.45%
6개월 성능:
+4.22%
1년 성능:
-3.18%
1일 변동 폭
$54.16
$56.24
1주일 범위
$54.16
$57.76
52주 변동 폭
$50.76
$66.28
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.53 | 10.83B | 3.24B | 348.90M | 717.02M | 1.7817 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Here Is Why BioMarin (BMRN) Is Projected to Rally - MSN
Game Over- No Self-Help Clock Reset for Mandatory Stay Request - The National Law Review
Trading the Move, Not the Narrative: (BMRN) Edition - Stock Traders Daily
BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition - marketscreener.com
BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN
Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - marketbeat.com
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance Australia
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BMRN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BioMarin at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) rated overweight at Wells Fargo despite Voxzogo phase 2 study discontinuations - msn.com
Here is Why BioMarin (BMRN) is Projected to Rally - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations - Insider Monkey
5 Quality Value Stocks Likely to Make a Comeback According to Analysts - Insider Monkey
BMRN SEC FilingsBiomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
(BMRN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Exploring High Growth Tech Stocks In The US Market March 2026 - simplywall.st
Vanguard disaggregates holdings; BioMarin (NASDAQ: BMRN) shows 0 shares reported - Stock Titan
BioMarin Bests Ascendis in Appeal Over Patent Suit Stay (1) - Bloomberg Law News
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Strong-Buy at Truist Financial - marketbeat.com
BioMarin (BMRN) down 13.6% since last earnings report: Can it rebound? - MSN
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
BioMarin Pharmaceutical (BMRN) reports positive results from ongoing trials of VOXZOGO - msn.com
Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes - Stock Titan
BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140 - Stock Titan
BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax - Stock Titan
BioMarin (BMRN) CEO reports tax-withholding share disposition - Stock Titan
Hudson Bay Capital Management LP Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin (BMRN) EVP Hubbard receives stock awards and withholds shares for tax - Stock Titan
BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares - Stock Titan
BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease - TipRanks
BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
3.83%
자본화:
|
볼륨(24시간):